Home > Boards > US OTC > Biotechs >

Bio-Matrix Scientific Group Inc. (BMSN)

Add BMSN Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator vegasdrummer, stockchaser64, cazual, The PoPo, Dr V, PetePham
Search This Board:
Last Post: 7/29/2014 4:41:51 PM - Followers: 1102 - Board type: Free - Posts Today: 43

(Majority-Owned Susidiary of BMSN)

Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN)
is a biotechnology company focused on identifying undervalued regenerative medicine applications
in the stem cell space and rapidly advancing these technologies through pre-clinical andPhase I/ II clinical trials.

Stem Cell Medicine


"Our business model is to acquire and form companies around
undervalued assets identified froma highly focused analysis of issued
patents in regenerative medicinethat have demonstrated proof of 


Dr. Ichim is one of the leading authorities in the
world on stem cell bi


With an emphasis on stem cell regenerative medicine


Our Business Model | Regen BioPharma

our business model 

Regen BioPharma has assessed over 20,000 stem cell related issued patents, narrowed down to 2000 patents with commercial applicability, and further identified 30 patents available for licensing. The company seeks to inlicense, take the product to, and through clinical safety and efficacy "signal" and spin out technologies.



Our Approach | Regen BioPharma




      In the "Conventional Model", stem cell companies are started with one basic technology, infrastructure is developed around that                       technology, then if the technology fails, significant resources are lost that have been used in the product-specific development

             Conventional Model
conventional model

             Regen BioPharma Model
regen model

Operational Plan

Month 1-2: Assembly of Team:
Regen intends to assemble a team of world-class leaders in the spheres of Technology, Intellectual Property assessment, valuation and Clinical development. Regen will seek to compile a team of Physician-Scientists with experience in the area of clinical trials for regenerative medicine/stem cell products, Regulatory experts who have successfully taken products through the FDA and corresponding agencies internationally, and Biotech Entrepreneurs who have track records of excellence in business formation and value optimization. -DONE
Month 1-4: Inlicensing of Intellectual Property:
The Company having already assessed over 20,000 issued patents and havingcompiled a shortlist of 30 targets; Regen will seek to execute licensing deals on an initial core of 3 technologies. Regen focuses onissued patents that have already passed preclinical studies but are not under clinical development. -DONE
Month 3-6: Interaction with Regulatory Agencies:
Regen intends to develop data packages for each of the technologies andinitiate interaction with Regulatory Agencies such as the FDA for initiation of trials.-DONE
Month 6-18: Clinical Implementation:
Regen intends to launch clinical trials with world-leading institutions to obtain human safety data and "signal" of therapeutic efficacy.  NEXT UP
Month 18-24: Exit:
It is intended that technologies "incubated" by Regen will be spun off either as separate companies, or sold to Large Pharma companies seeking to enhance their therapeutic pipeline.

"At present there exists a wealth of intellectual property that is 'collecting dust' in the corridors of Academia. Given the field of regenerative medicine and stem cell therapy is so young, and the business models are fuzzy at best in terms of valuation, we see this space as a unique opportunity for acceleration of clinical development/value optimization," said Bio-Matrix Chairman & CEO David Koos about its Regen BioPharma. "Valuations for stem cell companies that have passed the threshold of clinical safety, with signals of efficacy are astronomical. The $1.8 billion Mesoblast-Cephalon deal, as well as recent financings of private companies with as little as 3 patient data such as Promethera ($31 million) or Allocure with 16 patients ($23 million), is testimony to the extremely high valuations that are characteristic of this space."


Regen BioPharma Pipeline

HemaXellerate I™ FDA FILING
[Regen BioPharma filed an Investigational New Drug (IND) Application on February 5th, 2013.  Regen BioPharma has received approval from the FDA for the clinical protocol and the product manufacturing information for HemaXellerate I.  On May 9, 2014 Regen BioPharma submitted clarification on animal safety studies that the FDA requested with review anticipated within 30 days.]

HemaXellerate I is a cellular therapy designed to heal damaged bone marrow. HemaXellarate I utilizes a collection of cells harvested from the patient’s own adipose (fat) tissue to repair damaged bone marrow and stimulate production of blood cells . The initial application of HemaXellerate I will be the treatment of severe aplastic anemia, a rare and serious condition in which the bone marrow fails to make enough blood cells: red blood cells, white blood cells, and platelets. In practice, the physician is shipped a kit, which is used to collect adipose tissue. The tissue is sent to a processing facility, and a standardized cellular product is delivered in a ready-to-use manner for administration into the patient intravenously.

**The Company intends to seek Orphan Drug Designation under the Orphan Drug Act of 1983 from the US Food and Drug Administration for HemaXellerate I**

[Regen BioPharma is currently in the preclinical stage of development for dCellVax and plans to file an Investigational New Drug Application in August 2014]

The dCellVax therapeutic product is based on extracting blood from patients, growing a specialized type of immune cell from the blood called the "dendritic cell" and then subsequently genetically modifying the dendritic cell to become resistant to cancer's immune suppressive activity. It is known that cancer modifies the immune system by producing proteins which result in immune suppression. One such protein which cancer stimulates is an enzyme, indolamine 2,3 deoxygenase (IDO), which cancer turns on in dendritic cells. While dendritic cells are usually immune stimulators, dendritic cells found in cancer patients suppress the immune system as a result of expressing IDO.

The dCellVax therapeutic product uses patents that Regen BioPharma has in-licensed from Dr. Wei-Ping Min coupled with patents in-licensed from Benitec BioPharma.  By utilizing methods covered in both of these patents Regen BioPharma hopes to develop an immune-based, non-toxic cancer treatment initially targeting breast cancer.

HemaXellerate II™
[Regen BioPharma is currently in the preclinical stage of development for HemaXellerate II]

HemaXellerate II is intended to be a universal donor endothelial cell based therapeutic and is intended to be manufactured by obtaining cells from a part of the placenta called the “vascular lobules”. The cells are processed and utilized for the purpose of stimulating bone marrow hematopoetic stem cell repair and proliferation. The mechanism of action for HemaXellerate II is similar to HemaXellerate I whereby the harvested and processed cells would produce growth factors which would mediate the therapeutic effects of the product.


Managent Team | Regen BioPharma

David R. Koos, PhD, DBA

Chairman and Chief Executive Officer

David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 26 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or co-authored several peer reviewed journal articles primarily on biotechnology related subjects.

Thomas E. Ichim, PhD

Chief Scientific Officer and Board Member

Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. Dr. Ichim is a member of Vendevia Group, an innovative venture development organization focused on optimization of value in biotechnology ventures. He is scientific advisor to Orcrist Bio, Entest, and MBVaX. To date he has published 91 peer-reviewed articles and is co-editor of the textbook “RNA Interference: From Bench to Clinical Translation”. Ichim is an ad-hoc editor and sits on several editorial boards. Ichim is inventor on over 30 patents and patent applications. CV


Advisory Board | Regen BioPharma

Weiping Min, M.D.

Dr. Min is Associate Professor, Department of Surgery at the University of Western Ontario. His clinical research is focused on using siRNA to inhibit disease modalities, including cancer and organ rejection. He earned graduate and medical degrees from Nanchang University Medical School and the Ph.D. degree from Kyushu University.

David James Graham White, M.D., Ph.D.

Dr. White is a member of the Surgery and Immunology faculty of The Schulic School of Medicine, University of Western Ontario. He is one of the leading experts on using regenerative medicine transplant procedures to treat pancreatic conditions, including diabetes. He is also the Chief Scientific Officer of Sernova Corp and was formerly a Therapeutic Area Head for Novartis. He received the B.Sc. degree from the University of Surrey and the M.D. and Ph.D. degrees from Cambridge University.

David A. Suhy, PhD

Dr Suhy has a long-term interest in development of shRNA based therapeutics to treat human diseases. He is in the unique position of seeing of directing the research of a RNAi-based therapeutic from its earliest inception until it reaches clinical trials. Development of a shRNA therapeutic against the Hepatitis C virus (HCV) was initiated at Avocel in 2003. Financial constraints caused the company to shutter research operations in 2006.Upon raising venture capital, Tacere Therapeutics acquired the rights to the HCV family of drugs and brought back Dr. Suhy to head the program. Partnered with Pfizer shortly thereafter, this drug is their first foray into gene therapy-based approaches and is the first shRNA program partnered with a large pharma. Given Pfizer’s lack of experience in both areas, Dr. Suhy has played a pivotal role in its development as Tacere has continued to lead the research efforts for advancement of this product into the clinic and has stood side-by-side with Pfizer through all of the regulatory agency meetings.


Current Business Partners | Regen BioPharma





                        News and Recent Press Releases:

05/12/2014 12:30 Regen Biopharma, a Majority Owned Subsidiary of Bio-Matrix Scientific Group, Provides Update on HemaXellerate I(TM) IND...
03/06/2014 14:53 Bio-Matrix Scientific Group Inc. Announces Dividend Record Date to Receive Shares in Subsidiary, Regen BioPharma, Inc.
12/11/2013 09:35 Regen BioPharma Announces HemaXellerate I (TM) Efficacy Data in Animal Model of Aplastic Anemia

10/31/2013 11:35 Bio-Matrix Scientific Group's Regen BioPharma Retains Cook General Biotechnology for Contract Manufacturing of HemaXellerate I
10/09/2013 15:11 Bio-Matrix Scientific Group Inc. Announces 20 Million Share Regen BioPharma Dividend to Be Paid to Shareholders
09/26/2013 08:00 Bio-Matrix Scientific Group's Subisidiary Regen BioPharma Enters Into Preclinical Trials Agreement for HemaXellerate I..
09/25/2013 08:30 Bio-Matrix Scientific Group's Subsidiary Regen BioPharma Announces dCellVax Breast Cancer Immunotherapeutic Product
09/17/2013 10:06 Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
08/16/2013 13:47 Bio-Matrix Scientific Group Discusses Regen BioPharma's Cancer Immunotherapy Program
08/08/2013 09:47 Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
07/31/2013 14:36 Bio-Matrix Scientific Group Provides Update on Its Regen BioPharma's HemaXellerate I (TM) Clinical Program
06/07/2013 08:30 Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program
05/06/2013 08:30 Bio-Matrix Scientific Group's Regen BioPharma Acquires Cancer Vaccine Technology With Initial Focus on Breast Cancer
04/04/2013 16:09 Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development
03/18/2013 09:57 Regen BioPharma Receives IND # From FDA for HemaXellerate
02/26/2013 10:12 Bio-Matrix Scientific Group's Regen BioPharma Executes LOI to Acquire Issued US Patent Covering Cancer Gene-Silencing...
02/05/2013 10:35 Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I (TM) Stem Cell Drug For Aplastic...
01/24/2013 14:53 Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate (TM) Bone Marrow Failure Product



(Majority-Owned Susidiary of BMSN)


Entest BioMedical Inc.(OTCQB: ENTB) develops immuno-therapeutic treatments that address illnesses and maladies in both veterinary and human medicine.  Of specific interest to us are immunological vaccines for oncology (cancer vaccines) and veterinary clinic acquisitions.  The basis for the majority of our approaches is underpinned by leveraging the body's own reparative / immunological mechanisms - as opposed to using toxic chemicals.

Areas of Focus
Currently, Entest is focused on significant therapeutic therapies that show promise for the development of under-served market niches with potential high demand.


BMSN Transfer Agent:
Securities Transfer Corporation

2591 Dallas Parkway Suite 102

Frisco, Texas 75034

Phone - 469-633-0101

FAX 469-633-0088

#139335  Sticky Note BMSN FOLKS (READ HERE: DD).... PetePham 07/14/14 11:51:06 PM
#136931  Sticky Note BMSN*Valuation(s), FDA, & Orphan Drug Thoughts… cazual 06/18/14 10:19:05 AM
#134995  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 06/03/14 05:06:37 PM
#133857  Sticky Note Excellent Find by NEW4THIS: Dr V 05/23/14 07:56:10 AM
#132160  Sticky Note Updated BMSN/Regen BioPharma Timeline for IND Approval According The PoPo 05/12/14 03:01:43 PM
#140163   you lovely boy sante1 07/29/14 04:44:52 PM
#140162   Fully agree! It's simply another pinky. Not more ADVFN_franknstein 07/29/14 04:41:51 PM
#140161   I remember her posts. She was also FD2you 07/29/14 04:34:47 PM
#140160   Nah that was not the reason. ADVFN_franknstein 07/29/14 04:29:35 PM
#140159   So, the guy inside the BMSN loop with FD2you 07/29/14 04:19:38 PM
#140158   I highly suspect Stockchaser and Jack are the DRhos 07/29/14 04:15:25 PM
#140157   It's easy to be optimistic if you're the ADVFN_franknstein 07/29/14 04:11:47 PM
#140156   Then why are you here ??? I will inventor1 07/29/14 04:00:34 PM
#140155   my money my loss i'll take the risk/ Krisandtilly 07/29/14 03:38:23 PM
#140154   BMSN STOCK is false hope too all investors stockchaser64 07/29/14 03:31:48 PM
#140153   BMSN is in a quicksand situation ohmyohmy 07/29/14 03:26:56 PM
#140152   from Regen papers . "In the case of Krisandtilly 07/29/14 03:09:54 PM
#140150   D cellvax is breast cancer sup105 07/29/14 03:05:25 PM
#140149   What the price tag for D cell vax worth? Krisandtilly 07/29/14 02:59:35 PM
#140148   True =) sup105 07/29/14 02:58:14 PM
#140146   Some pump and dumps make more money for 72chevnj 07/29/14 02:54:20 PM
#140145   BMSN STOCK charts are going downward a stockchaser64 07/29/14 02:48:57 PM
#140144   D Cell Vax is vastly superior Quark's RNAi Krisandtilly 07/29/14 02:47:38 PM
#140143   yea every garbage news = pump and dump sup105 07/29/14 02:46:38 PM
#140142   "Although Regen's focus with Dr. Min is the Krisandtilly 07/29/14 02:45:11 PM
#140141   May have a reversal here 72chevnj 07/29/14 02:30:59 PM
#140140   This is the easiest stock to make money 72chevnj 07/29/14 02:30:20 PM
#140139   Its garbege scam news every two months sup105 07/29/14 02:28:24 PM
#140138   Any news yet? Wait a second...who am I wynston76 07/29/14 01:31:43 PM
#140137   The problem in the pinks is that folks FD2you 07/29/14 01:21:05 PM
#140136   Agreed! So many people, especially in developed countries, LootForMe2 07/29/14 12:58:45 PM
#140135   Great thought . I concur amigo. Perfect storm! Bmsn bone dry 07/29/14 12:34:09 PM
#140134   thanks for the .0026's anus!! BMSN $$$ chosenuno 07/29/14 12:30:45 PM
#140133   bids are moving up. time to take it chosenuno 07/29/14 11:32:17 AM
#140132   BINGO!!!!!!! trazbull 07/29/14 11:18:36 AM
#140131   Everyone here should be rejoicing with the silence. Kbro13 07/29/14 11:10:57 AM
#140130   With all your money. I ohmyohmy 07/29/14 10:53:38 AM
#140129   BMSN is best stock in penny land, no lab40 07/29/14 10:46:23 AM
#140128   BMSN STOCK lots of questions here no contact stockchaser64 07/29/14 10:44:06 AM
#140127   It honestly makes no difference to me. FD2you 07/29/14 10:43:29 AM
#140126   Thanks PoPo, nice find! Canadian Trader 07/29/14 10:40:39 AM
#140125   maybe one day soon you will realize the Beek 07/29/14 09:42:37 AM
#140124   Rverboatgambler:) I respect ohmyohmy 07/29/14 09:11:17 AM
#140123   BMSN DOWNTREND continue jack and i believe this stockchaser64 07/29/14 07:57:23 AM
#140122   I went thru this dance with Arena Pharma rverboatgambler 07/29/14 07:54:42 AM
#140121   A good legitimate business ohmyohmy 07/29/14 06:31:23 AM
#140120   $BMSN charts PetePham 07/28/14 11:52:21 PM
#140119   Maybe one day soon they will. Just FD2you 07/28/14 10:46:00 PM
#140118   Half a billion maybe RT1327 07/28/14 10:00:26 PM
#140117   Lol! Let's keep going. 3. Why Natureboy1 07/28/14 09:50:52 PM
#140116   Beek, what kind of volume are you expecting, rverboatgambler 07/28/14 09:37:58 PM
#140115   I think the words "patience" and "soon" should the Beek 07/28/14 09:16:02 PM
#140114   Longs aren't impatient as we know what we GM_FSJ 07/28/14 09:14:33 PM
#140113   Because there spoiled and want it know !! hangtough 07/28/14 09:03:32 PM
#140112   Darn straight. Why the impatience among so many longs? Goldstrike 07/28/14 08:55:05 PM